Targeting combinations of liposomal drugs to both tumor vasculature cells and tumor cells for the treatment of HER2-positive breast cancer

References

• Allen TM, Sapra P, Moase E, Moreira J, Iden D. (2002). Adventures in targeting. J Liposome Res, 12, 5–12.
   PubMed Web of Science ®Google Scholar
• Aragnol D, Leserman LD. (1986). Immune clearance of liposomes inhibited by an anti-Fc receptor antibody in vivo. Proc Natl Acad Sci USA, 83, 2699–2703.
   PubMed Web of Science ®Google Scholar
• Bolotin EM, Cohen R, Bar LK, Emanuel SN, Lasic DD, Barenholz Y. (1994). Ammonium sulphate gradients for efficient and stable remote loading of amphipathic weak bases into liposomes and ligandosomes. J Liposome Res, 4, 455–479.
   Google Scholar
• Brignole C, Marimpietri D, Gambini C, Allen TM, Ponzoni M, Pastorino F. (2003). Development of Fab’ fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma. Cancer Lett, 197, 199–204.
   PubMed Web of Science ®Google Scholar
• Carrick S, Parker S, Wilcken N, Ghersi D, Marzo M, Simes J. (2005). Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev, CD003372.
   Google Scholar
• Chaplin DJ, Hill SA. (2002). The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys, 54, 1491–1496.
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Pettit GR, Hill SA. (1999). Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res, 19, 189–195.
   PubMed Web of Science ®Google Scholar
• Chauhan VP, Stylianopoulos T, Martin JD, Popovic Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK. (2012). Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol, 7, 383–388.
   PubMed Web of Science ®Google Scholar
• Cheng WW, Allen TM. (2008). Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain Fv. J Control Release, 126, 50–58.
   PubMed Web of Science ®Google Scholar
• Denekamp J. (1982). Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer, 45, 136–139.
   PubMed Web of Science ®Google Scholar
• Denekamp J. (1984). Vascular endothelium as the vulnerable element in tumours. Acta Radiol Oncol, 23, 217–225.
   PubMed Web of Science ®Google Scholar
• Denekamp J. (1999). The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest, 29, 733–736.
   PubMed Web of Science ®Google Scholar
• Ebos JM, Kerbel RS. (2011). Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol, 8, 210–221.
   PubMed Web of Science ®Google Scholar
• Eichhorn ME, Strieth S, Dellian M. (2004). Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. Drug Resist Updat, 7, 125–138.
   PubMed Web of Science ®Google Scholar
• Folkman J. (1971). Tumor angiogenesis: therapeutic implications. N Engl J Med, 285, 1182–1186.
   PubMed Web of Science ®Google Scholar
• Folkman J. (1972). Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg, 175, 409–416.
   PubMed Web of Science ®Google Scholar
• Folkman J, Merler E, Abernathy C, Williams G. (1971). Isolation of a tumor factor responsible for angiogenesis. J Exp Med, 133, 275–288.
   PubMed Web of Science ®Google Scholar
• Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A. (1998). Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol, 16, 3439–3460.
   PubMed Web of Science ®Google Scholar
• Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. (2011). Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev, 91, 1071–1121.
   PubMed Web of Science ®Google Scholar
• Jain RK. (2001). Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med, 7, 987–989.
   PubMed Web of Science ®Google Scholar
• Jain RK. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58–62.
   PubMed Web of Science ®Google Scholar
• Koning GA, Kamps JA, Scherphof GL. (2002). Interference of macrophages with immunotargeting of liposomes. J Liposome Res, 12, 107–119.
   PubMed Web of Science ®Google Scholar
• Mayhew EG, Lasic D, Babbar S, Martin FJ. (1992). Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer, 51, 302–309.
   PubMed Web of Science ®Google Scholar
• Moase EH, Qi W, Ishida T, Gabos Z, Longenecker BM, Zimmermann GL, Ding L, Krantz M, Allen TM. (2001). Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. Biochim Biophys Acta, 1510, 43–55.
   PubMed Web of Science ®Google Scholar
• Noble CO, Kirpotin DB, Hayes ME, Mamot C, Hong K, Park JW, Benz CC, Marks JD, Drummond DC. (2004). Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets, 8, 335–353.
   PubMed Web of Science ®Google Scholar
• Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee KD, Woodle MC, Lasic DD, Redemann C. (1991). Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci USA, 88, 11460–11464.
   PubMed Web of Science ®Google Scholar
• Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E. (2000). Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res, 60, 722–727.
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M. (2006). Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res, 66, 10073–10082.
   PubMed Web of Science ®Google Scholar
• Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M. (2003). Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res, 63, 7400–7409.
   PubMed Web of Science ®Google Scholar
• Pool GL, French ME, Edwards RA, Huang L, Lumb RH. (1982). Use of radiolabeled hexadecyl cholesteryl ether as a liposome marker. Lipids, 17, 448–452.
   PubMed Web of Science ®Google Scholar
• Ruoslahti E. (1996). RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol, 12, 697–715.
   PubMed Web of Science ®Google Scholar
• Schiffelers RM, Fens MH, Janssen AP, Molema G, Storm G. (2005). Liposomal targeting of angiogenic vasculature. Curr Drug Deliv, 2, 363–368.
   PubMedGoogle Scholar
• Sitohy B, Nagy JA, Dvorak HF. (2012). Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res, 72, 1909–1914.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177–182.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med, 344, 783–792.
   PubMed Web of Science ®Google Scholar
• Thorpe PE. (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res, 10, 415–427.
   PubMed Web of Science ®Google Scholar
• Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. (2004). Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res, 64, 3731–3736.
   PubMed Web of Science ®Google Scholar
• van Osdol W, Fujimori K, Weinstein JN. (1991). An analysis of monoclonal antibody distribution in microscopic tumor nodules: consequences of a “binding site barrier”. Cancer Res, 51, 4776–4784.
   PubMed Web of Science ®Google Scholar
• Verreault M, Strutt D, Masin D, Anantha M, Yung A, Kozlowski P, Waterhouse D, Bally MB, Yapp DT. (2011). Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine. BMC Cancer, 11, 124.
   PubMedGoogle Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. (2001). First-line Herceptin monotherapy in metastatic breast cancer. Oncology, 61 Suppl 2, 37–42.
   PubMed Web of Science ®Google Scholar
• Wicki A, Rochlitz C, Orleth A, Ritschard R, Albrecht I, Herrmann R, Christofori G, Mamot C. (2012). Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth. Clin Cancer Res, 18, 454–464.
   PubMed Web of Science ®Google Scholar